Delhi High Court Declines to Halt National HPV Vaccination Campaign, Mandates Strict Oversight on Safety Protocols

NEW DELHI — In a major development for India’s national public health strategy, the Delhi High Court on Wednesday declined to issue an immediate stay on the Union Government’s Human Papillomavirus (HPV) immunisation drive for adolescent girls. Addressing a Public Interest Litigation (PIL) that raised concerns regarding vaccine safety and informed consent, the court ruled that there is no evidence of “immediate harm.” However, issuing a stern warning to public health authorities that “half-baked vaccines should not be administered,” the bench directed regulatory bodies to submit comprehensive responses regarding safety monitoring and protocol adherence within four weeks.

The ruling allows the government to proceed with its large-scale campaign under the Universal Immunisation Programme (UIP), which has delivered approximately 5.5 million doses of Merck’s quadrivalent HPV vaccine, Gardasil, to 14-year-old girls since its launch on February 28, 2026.

Court’s Ruling: Public Health Momentum Meets Judicial Scrutiny

The division bench, comprising Chief Justice D.K. Upadhyaya and Justice Tejas Karia, weighed the imperative of preventing cervical cancer against the petition’s safety allegations.

“There may not be long-term benefit, but there is no instant harm at the moment,” the bench observed during proceedings, noting that the government’s official data showed no fatalities or widespread severe adverse reactions requiring an emergency halt.

Despite refusing an interim injunction, the bench emphasized that strict standard operating procedures must be maintained. The court directed the Ministry of Health and Family Welfare, the Central Drugs Standard Control Organisation (CDSCO), and the Indian Council of Medical Research (ICMR) to file detailed affidavits by October 29, 2026, justifying the vaccine’s rollout and outlining safety protocols.

Government Safety Data vs. Petitioners’ Allegations

Representing the Union Government, Additional Solicitor General Chetan Sharma presented official monitoring data to reassure the court:

Government counsel affirmed that regulatory evaluations preceded the campaign’s launch and stressed that participation remains strictly voluntary, requiring prior informed consent from parents or legal guardians.

Conversely, the PIL—filed by gynaecologist Dr. Sujata Mittal and health entrepreneur Jitendra Chouksey—presents a starkly different narrative. The petition cites individual cases of severe neurological complications, including a March 2026 incident in Tamil Nadu where a 14-year-old girl reportedly suffered motor weakness, blurred vision, loss of voice, and required intensive care unit (ICU) admission shortly after receiving the vaccine.

The petitioners further allege constitutional violations under Articles 19 and 21, arguing that setting targets for frontline health workers (such as Accredited Social Health Activists, or ASHA workers) creates coercive pressure on families, compromising genuine consent.

The Public Health Burden: Why HPV Vaccination Matters

Cervical cancer remains one of the most formidable health challenges for women in India. According to Ministry of Health estimates, the disease claims roughly 77,000 lives annually in the country.

       [ High-Risk HPV Strains (16 & 18) ]
                        │
                        ▼
  [ ~70% of Global Cervical Cancer Cases ]
                        │
                        ▼
 [ Target: 90% Vaccination Coverage by Age 15 ]

Human Papillomavirus is the primary cause of cervical malignancies, with high-risk types 16 and 18 responsible for approximately 70% of cases worldwide. To combat this burden, the World Health Organization (WHO) established a global strategy targeting elimination—defined as fewer than 4 cases per 100,000 women per year—built on three key pillars:

• Vaccination: 90% of girls fully vaccinated by age 15.

• Screening: 70% of women screened with a high-performance test by ages 35 and 45.

• Treatment: 90% of women identified with cervical disease receiving proper care.

Extensive clinical literature demonstrates the prophylactic efficacy of HPV vaccines. Systematic reviews confirm up to 99% efficacy in preventing high-grade precancerous lesions (CIN2/CIN3) caused by targeted strains among individuals not previously exposed to the virus. Real-world population studies from Scandinavia have similarly recorded dramatic declines in invasive cervical cancer rates among cohorts vaccinated prior to age 16.

Complexities and Diverse Perspectives

While public health organizations strongly advocate for immunisation, independent experts acknowledge the multi-faceted nature of cervical cancer prevention and vaccine deployment.

Broader Risk Factors

The petitioners pointed out that viral infection interacts with numerous co-factors, including:

• Hygiene standards and socioeconomic conditions

• Age at marriage and parity (number of pregnancies)

• Immunological status and tobacco use

They argue that a single-intervention approach should not eclipse holistic reproductive health infrastructure, regular screening, and public health education.

Historical Context and Monitoring Transparency

The legal challenge also referenced a 2013 Parliamentary Standing Committee report that previously investigated irregularities during early observational studies of HPV vaccines in India. Citing historical lapses in documentation and global litigation history involving vaccine manufacturers, critics emphasize that India needs a fully transparent, district-level Adverse Events Following Immunisation (AEFI) tracking system open to public review.

Policy Implications and Next Steps

The Delhi High Court’s directive places the national HPV campaign under active judicial supervision without interrupting public health access. As health authorities prepare their affidavits for the October 29, 2026 hearing, the focus shifts toward operational accountability:

1. Verification of Consent: Ensuring local health networks strictly uphold voluntary participation without implicit quotas.

2. Robust AEFI Tracking: Strengthening real-time clinical monitoring for rare adverse events across all Union Territories.

3. Integrated Care: Combining primary prevention (vaccines) with secondary prevention (routine pap smears and HPV DNA screening).

Practical Guidance for Parents and Families

For parents evaluating the HPV vaccine for their children, medical consensus offers several practical considerations:

• Consult Healthcare Providers: Discuss your child’s medical history, potential allergies, and immediate side effects (such as localized soreness, low-grade fever, or brief dizziness) with a qualified physician.

• Understand Consent: Review the official consent documentation provided by school or community health programs before authorization.

• Maintain Screenings: Vaccination serves as primary prevention against specific high-risk strains; it does not replace the need for routine cervical cancer screenings later in adult life.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://health.economictimes.indiatimes.com/news/policy/delhi-hc-refuses-to-halt-centres-hpv-immunisation-campaign-but-warns-of-half-baked-vaccines/132729929?utm_source=latest_news&utm_medium=homepage